- Home
- SFWL vs QNCX Comparison
SFWL vs QNCX Comparison
Compare SFWL & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFWL
- QNCX
- Stock Information
- Founded
- SFWL 2001
- QNCX 2012
- Country
- SFWL China
- QNCX United States
- Employees
- SFWL N/A
- QNCX N/A
- Industry
- SFWL Trucking Freight/Courier Services
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SFWL Industrials
- QNCX Health Care
- Exchange
- SFWL Nasdaq
- QNCX Nasdaq
- Market Cap
- SFWL 82.3M
- QNCX 90.8M
- IPO Year
- SFWL 2023
- QNCX 2019
- Fundamental
- Price
- SFWL $1.15
- QNCX $1.60
- Analyst Decision
- SFWL
- QNCX Strong Buy
- Analyst Count
- SFWL 0
- QNCX 6
- Target Price
- SFWL N/A
- QNCX $8.00
- AVG Volume (30 Days)
- SFWL 24.3K
- QNCX 124.9K
- Earning Date
- SFWL 08-27-2025
- QNCX 11-12-2025
- Dividend Yield
- SFWL N/A
- QNCX N/A
- EPS Growth
- SFWL 31.68
- QNCX N/A
- EPS
- SFWL 0.14
- QNCX N/A
- Revenue
- SFWL $540,461,000.00
- QNCX N/A
- Revenue This Year
- SFWL N/A
- QNCX N/A
- Revenue Next Year
- SFWL N/A
- QNCX N/A
- P/E Ratio
- SFWL $8.11
- QNCX N/A
- Revenue Growth
- SFWL 21.10
- QNCX N/A
- 52 Week Low
- SFWL $0.86
- QNCX $0.69
- 52 Week High
- SFWL $1.60
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- SFWL 57.68
- QNCX 47.89
- Support Level
- SFWL $1.10
- QNCX $1.56
- Resistance Level
- SFWL $1.18
- QNCX $1.65
- Average True Range (ATR)
- SFWL 0.09
- QNCX 0.08
- MACD
- SFWL 0.01
- QNCX 0.00
- Stochastic Oscillator
- SFWL 51.72
- QNCX 64.65
About SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.